Divis Laboratories Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 68.4. ROE: 16.5%. This stock is not currently in the Nifty 500 momentum outperformers list.
Earnings deceleration risks from management commentary
Trigger: Divi's CS growth thesis requires 3 dedicated project approvals moving simultaneously in CY2027 — regulatory sequencing is outside management's control and the most material swing factor for FY28 earnings
Monitor: regulatory
Trigger: While direct API-level impact is limited (management clarified exemptions cover intermediates and final APIs), basic chemical raw material cost inflation could squeeze margins in generics segment where pricing is already competitive
Monitor: commodity
Trigger: Absence of hedging policy means INR appreciation directly compresses realization on INR8,000cr+ annual export revenue; with 89% export mix, 2-3% INR move is ~150-200cr PAT impact
Monitor: fx
Trigger: Nascent but worth monitoring — Europe + US is 73% of Divi's export base; any tariff shift in either direction affects realized pricing on the dominant revenue pool
Monitor: geopolitical
Key quotes from recent conference calls
“So we are assuming depending on all regulatory approvals happening on time, somewhere in Q3, Q4 of 2027 is when the commercial volumes will start moving [Risk (regulatory): MEDIUM]”
“recent policy changes such as China's withdrawal of export tax rebates on certain products, which may result in selective pricing pressures over time... we have increased our domestic supplier base to 78% of the procurement [Risk (commodity): MEDIUM]”
“We are not hedging. We are evaluating at this point based on the overall scenario in the market [Risk (fx): LOW]”
“Relating to this India EU FTA, what we have seen, any opportunity that you identify out of that in the -- if not immediately in the medium term, sir? Because anyway, Europe is our biggest trade partner? It's too early for us to comment on that. It just happened recently, right? [Risk (geopolitical): LOW]”
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Divis Laboratories Ltd's latest quarterly results (Mar 2026) show
Divis Laboratories Ltd's current PE ratio is 68.4x.
Divis Laboratories Ltd's price-to-book ratio is 10.7x.
Divis Laboratories Ltd's fundamental strength based on key financial ratios
Divis Laboratories Ltd has a debt-to-equity ratio of N/A.
Divis Laboratories Ltd's return ratios over recent years
Divis Laboratories Ltd's operating cash flow is positive (FY2026).
Divis Laboratories Ltd's current dividend yield is 0.44%.
Divis Laboratories Ltd's shareholding pattern (Mar 2026)
Divis Laboratories Ltd's promoter holding has remained stable recently.
Divis Laboratories Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Divis Laboratories Ltd has 4 key risks worth monitoring
In Q3 FY26, Divis Laboratories Ltd's management highlighted
Based on quantitative research signals, here is why Divis Laboratories Ltd may be worth studying
Divis Laboratories Ltd investment thesis summary:
Divis Laboratories Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
